Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,317 from $1,264 and keeps an Overweight rating on the shares. The firm raises its 2026-2030 Vyvgart estimates by 5%-15%, and highlights FY26 consensus estimate of $5.6B as too low given the growth trajectory. Wells estimates $6.5B assuming single-digit quarter-over-quarter growth in Q1 and low double-digit quarter-over-quarter growth Q2-Q4.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- argenx Wins FDA Priority Review for VYVGART in Seronegative gMG
- Argenx: Strong Vyvgart Execution, Deep Pipeline, and Vision 2030 Drive Compelling Buy-Rated Upside
- Argenx announces FDA acceptance of Vyvgart sBLA for priority review
- Argenx: Sustained Growth and Strategic Pipeline Upside Underpin Buy Rating
- Argenx: Sustained Vyvgart Momentum and Expanding FcRn Pipeline Underpin Buy Rating and Attractive Risk‑Reward